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MicroRNAs (miRNAs) have been shown to play a significant role in cancer progression 
and metastasis through their regulation of gene expression to activate epithelial-mesenchymal 
transition (EMT). Understanding the genetic and molecular basis for how microRNAs induce 
EMT’s reciprocal mechanism, mesenchymal-epithelial transition (MET), is vital as metastatic 
disease is highly lethal. This study aims to identify genes involved in MET across two cancer 
types based on microRNA overexpressions that have previously been shown to induce MET in 
mesenchymal-like ovarian or prostate cancer cell lines. It also aims to understand how the 
same microRNAs behave in similar mesenchymal cell-lines. To elucidate the ability of different 
microRNAs to induce the same process of MET in two reproductive cancer cell lines, 
transfections to overexpress miR-429, miR-203a, and miR-205 in both ovarian cancer and 
prostate cancer cell lines, HEY and PC3, respectively, were performed. Using microarray 
analysis, differentially expressed genes were identified and comparisons of these genes to 
known EMT/MET genes was done to narrow down a set of genes important in both ovarian and 
prostate cancer MET processes. We show that miR-429 induces MET in both HEY and PC3 cells, 
but not through similar pathways, and that overexpression of miR-203a and miR-205 induced 
MET in either HEY or PC3, but not both. ZEB1 was identified as a gene candidate for siRNA 
knockout to recapitulate MET and further elucidate mechanisms of the three microRNAs 







Ovarian cancer is highly metastatic and is the most lethal of gynecologic cancers [1]. 
Prostate cancer is also the most lethal of the male reproductive system cancers and is the 
second-leading cause of cancer-related deaths in males. Survival rates of later stages of 
metastatic ovarian and prostate cancer are markedly lower than when they are detected in 
their earlier stages. The lethality of these more advanced cancers lies in their highly metastatic 
nature. Current chemotherapies, radiation therapies, and surgeries are not guaranteed to treat 
every location of disease in the body, which increases the possibility of recurrence of the 
cancer.  
The processes underlying metastasis manifest differently in diverse cancer types, and 
each has varying locations of metastases in the body [13]. This holds true for prostate and 
ovarian cancer as well, where prostate cancer metastasizes strongly to the bone, and ovarian 
cancer metastasizes primarily to the abdominal cavity [13, 14]. Nevertheless, an underlying 
cellular mechanism by which primary tumor cells of both cancers undergo metastasis is known 
as epithelial-to-mesenchymal transition (EMT) [2]. During EMT, the intercellular adhesions of 
epithelial cells are disrupted, the cells become less proliferative, and the cells become more 
motile and invasive by becoming more mesenchymal-like before intravasation in metastasis [3]. 
Phenotypically, epithelial cells are characterized by a cuboidal shape, while mesenchymal cells 
are longer and thinner, thus allowing for greater motility. Upon arrival to the secondary tumor 
site, the cells revert to the epithelial state by undergoing mesenchymal-to-epithelial transition 
(MET). Inducing MET in a mesenchymal cell reverses the EMT process and could create an 
environment for the tumor to be more sensitive to current chemotherapies such as cisplatin 
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that target epithelial cell types. The specific mechanisms by which EMT/MET occurs in prostate 
and ovarian cancer cells have been shown to be different with respect to each cancer type 
[15,16]. However, an underlying factor shared by many cancer types is the multitude of roles 
microRNAs have been shown to play in cancer progression [17]. One such role is the 
involvement of members of the miR-200 family of microRNAs in a double-negative feedback 
loop with ZEB1 and ZEB2 to initiate EMT [18]. This double-negative feedback loop is a process 
shared by multiple cancer types, which may show similar involvements for the same miRNA in 
multiple cancer types [18].  
MicroRNAs (miRNA) are short, non-coding RNAs involved in the regulation of gene 
expression by either translational repression or degradation of target messenger RNAs 
(mRNAs), and have been shown to contribute to cancer development through their role of up 
regulating or down regulating different genes through loss and gain of miRNA function, 
respectively [4]. MicroRNAs can also be involved in the post-transcriptional regulation of mRNA, 
thus affecting protein level independently of the varying mRNA expression seen in cancer 
development [8]. Due to the highly conserved seed regions of microRNAs, which bind to the 3’- 
untranslated region (UTR) of their target mRNAs, a single microRNA can regulate many gene 
targets simultaneously, making these small RNAs a useful regulator of gene expression [9]. This 
endogenous regulation of multiple genes at once by a single miRNA presents an opportunity to 
further explore the effects of a single microRNA on multiple types of cancer, and specifically, if 
a single microRNA can induce the same processes, such as mesenchymal-epithelial transition 
(MET) across diverse types of cancer.  
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Previous studies have established the role of various microRNAs in a miRNA-mediated 
regulatory pathway that influences MET. An example is the overexpression of miR-429, a 
member of the miR-200 family that contributes to the induction of MET in metastatic ovarian 
cancer cells (HEY) [5]. Overexpression of miR-203 has been shown to induce MET in metastatic 
prostate cancer cells (PC3) [6]. It has also been reported that miR-205 is a tumor suppressor in 
prostate cancer that targets c-SRC, and overexpression of it in PC3 cells lessened cell 
proliferation, invasion, and tumor growth [7]. These microRNAs seem to induce similar 
phenotypic changes conducive with MET in varying cell lines. However, while previous studies 
have looked at these microRNAs in the context of a single cell line of interest and shown that 
they induce MET, they have not explored the effects of the same microRNA in a different 
cancer cell line. Doing so may show some overlap in the underlying MET mechanisms across 
different metastatic cell types, in this case, prostate and ovarian cancer, because microRNAs 
have multiple gene targets. This endogenous characteristic of microRNAs having multiple gene 
targets makes it possible that there may be some overlap in a single microRNA’s gene targets 
that induce MET in multiple cell lines. Identifying what common gene targets are shared by a 
single microRNA that induces MET in different cancer cell lines presents an opportunity to 
develop a better biomarker or therapeutic agent to treat a broad range of cancers in the future, 
as well as elucidate an underlying mechanism that multiple cancers share in the induction of 
MET.   
This study, by overexpressing miR-429, miR-203a, and miR-205 in ovarian cancer and 
prostate cancer cells, aims to explore the genetic and molecular basis for EMT/MET in the two 
mesenchymal-like cell lines, HEY and PC3. We have been able to induce MET using the same 
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microRNA, miR-429, in both HEY and PC3 cells, and we have been able to identify trends in 
differential expression of genes induced with the three microRNAs of interest. We have also 
been able to identify ZEB1 as a gene candidate for future short-interfering RNA (siRNA) 
knockout as it is implicated in inducing MET in both cell lines and is a target of all three 
microRNAs. SiRNA knockout of ZEB1 will be done in future work to postulate a mechanism of 
action for MET in both cell lines as well as to gain an understanding of ZEB1’s direct and indirect 
effects in the setting of MET on both mesenchymal-like cell lines. Short-interfering RNAs are like 
microRNAs in that they induce mRNA degradation or silencing, but where miRNAs are naturally 
occurring nucleic acids that typically target hundreds of genes, siRNAs are designed and 
synthesized to target a single gene. Successful siRNA knockout of these candidate genes 
determined in this study could eventually lead to the development of versatile therapeutic 




This experiment was conducted by overexpressing miR-429, miR-203a, and miR-205 in 
mesenchymal-like ovarian and prostate cancer cell lines to observe differences in MET 
induction between the two cell lines transfected with different microRNAs. These observations 
were addressed objectively using CellProfiler to deduce the samples that induced MET. 
Microarray analysis was used to determine differentially expressed genes. These genes were 
compared against putative direct miRNA targets of miR-429, miR-203a, and miR-205 to 
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determine possible direct/indirect relationships between the gene expression inducing MET 
and its respective microRNA. The results of the microarray analysis of differentially expressed 
genes between treatments was also used to further elucidate important genes involved in MET 
that may be candidates for future siRNA (short-interfering RNA) knockout.  
 
Transfection 
The cell lines used for this 
experiment were HEY and PC3, a 
mesenchymal-like human ovarian and 
prostate cancer cell line, respectively. To 
perform the transfection of the HEY and 
PC3 cells with miR-429, miR-203a, and 
miR-205, each combination of HEY and 
PC3 with the three miRNAs was done in a 
separate 12-well plate, for a total of six 
treatments. For each transfection experiment, the 12-well plate was seeded with an 
appropriate number of cells: 40,000 cells/well for PC3 and 25,000 cells/well for HEY. The 
number of cells for each cell line was different because HEY cells grow better in smaller 
numbers than PC3 cells do. Nine wells were seeded with the appropriate number of cells, and 
the last three cells contained PBS to balance the plate. The cells grew with complete RPMI 1640 
media containing fetal bovine serum and antibiotics (known as R10 media) in 37°C until they 
reached their exponential phase of growth, at about 24 hours post-seeding. At the 24-hour 
Figure 1: 12-well plate set-up. Cell includes either HEY or PC3 
cells. MiR-X includes miR-429, miR-203a, or miR-205. MiR-NC is 




mark, the cells were transfected with the microRNA of interest (miR-429, miR-203a, and miR-
205) and the negative control microRNA (miR-NC) using Lipofectamine 2000 and Opti-MEM 
media. The negative control samples were transfected with miR-NC, a negative control 
microRNA that does not target any genes that are targeted by miR-429, miR-203a, or miR-205, 
but is used to normalize the effect of transfecting cells with Lipofectamine 2000. Lipofectamine 
2000 is the transfection reagent that allows the uptake of microRNA into the cell and Opti-MEM 
media contains reduced levels of fetal bovine serum, making transfection more effective. Three 
wells containing cells were transfected with the microRNA of interest and another three wells 
were transfected with miR-NC. Each well serves as a single replicate. The last three wells of cells 
were allowed to grow with no interference. Four hours after transfection, the Opti-Mem media 
was changed to R10 media, and the cells were left to incubate in 37°C for another 44 hours. At 
the 48-hour mark, pictures of the cells were taken and the cells were collected and frozen for 
future RNA extraction and microarray analysis. Each combination of cell type and microRNA of 
interest was transfected with a negative control in a separate 12-well plate.  
Of note, the PC3 cells transfected with miR-429 sample, along with its own negative 
control sample, was repeated with two replicates for miR-429 and miR-NC, and included in the 
analysis with its own negative control separate from that of the other samples. 
 
RNA Extraction 
RNeasy Micro Kit (Qiagen, Germantown, MD) protocols were followed for RNA 
extraction from the HEY and PC3 cells. The RNA concentration was checked using Nanodrop 
Spectrophotometer (Thermo Fisher Scientific, Grand Island, NY). RNA quality for all samples 
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was verified using Agilent RNA 6000 Pico KIT for Bioanalyzer (Agilent Technologies, Santa Clara, 
CA). The RNA from the extractions was amplified with Applause 3’-Amp System (NuGEN 
Technologies, San Carlos, CA) and labeled with the Encore Biotin Module (NuGEN Technologies) 
to produce a cDNA suitable for hybridizing to GeneChip Human Genome U133 2.0 Array 
(Affymetrix, Santa Clara, CA) following manufacturers’ recommendations.  
 
Microarray Data Analysis 
Gene expression for each sample was measured by microarray. Microarray analysis was 
done using the Affymetrix Human Genome U133 Plus 2.0 Array as previously described [10]. 
Twenty-five individual gene expression profiles were generated from the HEY and PC3 samples 
with miR-429, miR-203a, miR-205, and miR-NC. MiR-429 and miR-NC transfected into PC3 
samples, there were two replicates for each microRNA. This gave a total of 5 expression profiles 
for miR-429 samples and eight expression profiles for the negative control samples. The 25 
Affymetrix .CEL files were processed using the Affymetrix Expression Console (EC) Software 
Version 1.1 using the Robust Multi-Array Average (RMA) normalization method. The normalized 
expression values from all eight samples were log2 transformed. 
The initial data contained 23,033 gene expression values from the Affymetrix Human 
Genome U133 Plus 2.0 chip. The log2-transformed expression values were averaged across the 
replicates for each combination of HEY or PC3 transfected with a single microRNA (i.e. HEY cells 
transfected with miR-429 or PC3 cells transfected with miR-NC). A two-tailed modified T-test (p 
< 0.05) was applied to identify genes that had significantly different expressions between the 
microRNA sample and negative control sample for each treatment. After determining 
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statistically significant expression values, the base two logarithm fold change (log2(FC)) of 
expression values was determined. The log2(FC) was calculated by subtracting the average 
negative control value from the average microRNA treatment value. Positive and negative 
log2(FC) values showed over-expression and under-expression of the gene, respectively. The 
23,033 genes were then filtered based on statistically significant differential expression (p < 
0.05) and a fold change ratio cutoff of 1.5. If log2(FC) values were greater than log2(1.5) or less 
than -log2(1.5), and statistically significant (p < 0.05), they were denoted to be differentially 
expressed (DE). 
 
Analysis of microRNA putative direct targets with differentially expressed genes 
 The differential gene expression results were compared against putative direct targets 
of miR-429, miR-203(a), and miR-205 for each respective sample to determine how much of the 
effects of each microRNA are indirect or direct with respect to the other samples. The miRNA 











miR-429, miR-203a, miR-205 and miR-NC overexpressed in HEY and PC3 samples  
Figure 2: Overexpression of miR-429, miR-203a, miR-205, and miR-NC in HEY and PC3 cells (scale bar = 50 µm). 
Green boxes indicate treatments that induced MET (classified based on eccentricity values of treatments in Figure 
3), and red boxes indicate treatments that did not induce MET. 
 Negative Control miR-429 miR-203a miR-205 
HEY 
    
PC3 
    
Figure 3: Cell eccentricity values of transfected HEY and PC3 cells. Values represent mean ± SEM (n=251-544 cells 
analyzed per group). Asterisks represent significant differences from the negative control (*P< 0.0001, NS = not 



























The initial transfection experiment with the three microRNAs and HEY and PC3 cells 
showed MET-like phenotypic changes in four treatments after 48 hours (Figure 2). The objective 
determination of MET occurring was done using an eccentricity comparison between the 
miRNA of interest-transfected treatment and its corresponding negative control, where a lower 
eccentricity value was expected for the treatments that induced MET. The eccentricity 
comparison was done using CellProfiler with images taken at 48 hours post-transfection (Figure 
3). All eccentricity values of HEY samples treated with either miR-429, 203a, or 205 were 
compared against “HEY_miR-NC.” PC3 samples had two negative controls, “PC3_miR-NC_1” 
and “PC3_miR-NC_2,” the latter of which was used to compare against “PC3_miR-429” and the 
former of which was used against the PC3 cells overexpressed with miR-203a and miR-205 
treatment. The treatments significant for a difference in eccentricity (Mann-Whitney U, p < 
0.0001) were miR-429-overexpressed in HEY and PC3, miR-203a-overexpressed in PC3, and 
miR-205-overexpressed in HEY cells. These four treatments are identified as treatments that 
induce MET from this point forward. MiR-203a overexpressed in HEY cells and miR-205 in PC3 
cells were not significantly different in eccentricity and therefore did not induce MET. 
Phenotypic observations from Figure 2 shows that HEY and PC3 cells transfected with miR-NC 
demonstrate the typical mesenchymal-like cell phenotype where the cell is elongated and have 
projections from the cell body. HEY and PC3 cells with miR-429 overexpressed, HEY cells with 
miR-205 overexpressed, and PC3 cells with miR-203a overexpressed exhibit less extreme 
elongation and are more cuboidal in shape, lacking strong projections from the cell bodies 
characteristic of mesenchymal-to-epithelial transition. The other treatments, miR-205 
overexpressed in PC3 and miR-203a overexpressed in HEY, did not display phenotypic changes 
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characteristic of MET. For example, MiR-205 overexpressed in PC3 cells still exhibited long 
projections, indicative of the cell’s motility as a mesenchymal cell [19]. MiR-203a 
overexpression in HEY cells also did not show a more cuboidal-shaped phenotype and showed 
strong projections in individual cells. The phenotypic subjective observations are consistent 
with the objective eccentricity analysis to identify miR-429 in HEY and PC3 cells, miR-203a in 
PC3 cells, and miR-205 in HEY cells as the treatments that induced MET. 
During the initial transfection experiment, it is worth noting that transfection of PC3 
cells was more difficult compared to HEY cells, because after 48-hours post transfection, more 
cells had died in the PC3 samples. This may be due to a higher sensitivity of PC3 cells to the 
transfection reagent, Lipofectamine 2000, which can exhibit cytotoxic effects on cells. 
 
Each treatment showed differing amounts of differentially expressed genes 
Differentially expressed genes were determined 
based on two criteria: two-tailed modified T-test (using R) 
evaluated at p < 0.05 and fold change (FC) ratio cutoff of 
1.5 (Table 1). The number of differentially expressed genes 
is without regard to direction of expression. For the miR-
429 samples, 7,179 and 1447 genes were differentially 
expressed for HEY and PC3, respectively. For miR-203a samples, 1,389 and 6,877 genes were 
differentially expressed for HEY and PC3, respectively. Lastly, for miR-205-overexpressed 
samples, 9,146 and 5,806 genes were differentially expressed for HEY and PC3.  
 HEY PC3 
miR-429 7179 1447 
miR-203a 1389 6877 
miR-205 9146 5806 
Table 1: Number of differentially expressed (DE) 
genes after 48-hour transfection of microRNAs. 
Criteria for DE: P < 0.05, FC = 1.5. 
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Comparison of direct putative miRNA targets with differentially expressed genes 
 
Figure 4: Percentage of differentially expressed genes that are putative direct targets of their respective microRNA 
(miR-429, miR-203a, and miR-205) 
The number of putative direct targets obtained from microrna.org for miR-429, miR-
203a, and miR-205, were 4141, 5345, and 2941 genes, respectively. For miR-429, these 4,141 
genes were compared against the 7,179 DE genes in HEY and 1,447 DE genes in PC3. The same 
was done for the respective number of direct targets of miR-203a and miR-205 with their 
transfected HEY and PC3 samples (Figure 4). Of the 7,179 DE genes resulting from miR-429 
transfected in HEY, 19% are putative direct targets of miR-429. For PC3 transfected with HEY, 
27% of the 1,447 genes are direct putative gene targets of miR-429. For HEY and PC3 
transfected with miR-203a, 23% and 20% of the differentially expressed genes are putative 
direct targets of miR-203a, respectively. For HEY and PC3 cells transfected with miR-205, 12% 











































Finding MET-implicated genes across all treatments that induced MET  
After determining which treatments induced changes characteristic of MET and 
determining the number of differentially expressed (DE) genes in each, the DE genes between 
these samples were compared to find genes in common that may be implicated in MET. To 
filter the DE genes to find those that may be implicated in MET across both cell lines, a series of 
Venn-diagram comparisons and their intersections of genes found to be in common were made 
Figure 5: Venn diagram comparisons of DE genes between samples which showed MET. Numbers in parenthesis are 
the number of DE genes for each treatment included in the venn diagram comparisons. Section outlined in red with 
312 genes is most common list of MET-implicated genes among the four samples. 
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between the four microRNA treatments that induced MET (Figure 5). There were 698 genes in 
common between the HEY and PC3 cells that were both treated with miR-429. Between both 
HEY samples that showed MET (miR-429 and miR-205) they shared 4,341 genes. The two PC3 
samples that demonstrated MET (miR-429 and miR-203a) shared 767 genes. There were 312 
genes (outlined in red) which are the most specific set of genes because of the induction of 
MET in the cells. These 312 genes are the result of all the treatments that showed MET. From 
these 312 genes, henceforth denoted “312 MET genes” we can further deduce what genes can 
be candidates for siRNA knockdown. 
 
Narrowing down the 312 MET gene list to identify potential siRNA knockdown candidates 
After determining the 312 genes that are differentially expressed in all treatments that 
were involved in MET, we wanted to narrow down our gene list to those essential for MET. 
Once identified, subsequent siRNA knockdown can be employed to attempt to recapitulate the 
effect of MET from overexpression of the microRNAs in their respective cell lines. Attempting to 
recapitulate MET with siRNA knockdown will help elucidate a mechanism of action for the 
miRNAs inducing MET in the different cell lines. To identify the putative target genes, we 




PC3-203a HEY-205 HEY-429 PC3-429 
logFC p value logFC p value logFC p value logFC p value 
GNG11 - -1.398 1.15E-08 -1.642 5.98E-10 -1.282 5.22E-08 -0.851 2.50E-05 
TCF4 miR-203a -0.847 1.13E-07 -1.288 5.17E-11 -0.866 7.78E-08 -0.844 1.21E-07 
WNT5A 
miR-429, 
205 -1.017 8.51E-09 -1.834 7.29E-14 -1.033 6.36E-09 -0.646 1.14E-05 
ZEB1 
miR-429, 
203a, 205 -1.185 1.71E-08 -1.877 2.51E-12 -1.974 8.86E-13 -1.094 6.87E-08 
Table 2: Downregulated 312 MET genes confirmed in EMT literature list and potential siRNA candidates 
19 
 
Profiler™ PCR Array Human Epithelial to Mesenchymal Transition (Qiagen) [20]. This 
comparison gave five genes in both gene lists: GNG11, KRT7, TCF4, WNT5A, and ZEB1. These 
genes, except for KRT7, were downregulated, and these are of interest since in recapitulation 
with siRNA knockdown, we would expect to see downregulation of the gene candidates (Table 
3). ZEB1 was the only gene in the resulting four downregulated MET genes that was a target of 
all three microRNAs used in the experiment. 
 
Pathway enrichment of all differentially expressed genes 
 To evaluate what pathways were enriched in each microRNA treatment sample, 
pathway enrichment analysis was performed using ToppGene (with an FDR correction p < 0.05) 
on each set of differentially expressed genes as well as on the 312 MET gene list. The top 50 
pathway enrichments for each DE gene treatment based on p-value, and all shared pathways of 
the DE gene treatments and 312 MET genes are reported in Supplementary Tables (Appendix). 
The top five pathways enriched of 160 in the HEY+miR-429 treatment are gene expression, 
organelle biogenesis and maintenance, mitochondrial translation initiation, mitochondrial 
translation elongation, and mitochondrial translation (ST1, Appendix). The five pathways 
enriched in the HEY+miR-203a treatment are cytokine-cytokine receptor interaction, starch and 
sucrose metabolism, digestion of dietary carbohydrate, extracellular matrix organization, and 
rheumatoid arthritis (ST2, Appendix). The top five pathways of 255 enriched in the HEY + miR-
205 are gene expression, metabolism, metabolic pathways, cell cycle (mitotic), and asparagine 
N-linked glycosylation (ST3, Appendix). For PC3+miR-429, the top five pathways enriched of 13 
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are cell junction organization, proteoglycans in cancer, cell-cell junction organization, Hippo 
signaling pathway, and pathways in cancer (ST4, Appendix). The top five pathways enriched of 
261 for PC3+miR-203a are gene expression, metabolism of proteins, metabolism, rRNA 
processing in the nucleus and cytosol, and organelle biogenesis and maintenance (ST5, 
Appendix). The top five pathways enriched of 218 for PC3 + miR-205 are interferon alpha/beta 
signaling, gene expression, mitotic cell cycle, metabolism/metabolism of proteins, and ER-
phagosome pathway (ST6, Appendix). The top five pathways of 136 that the 312 MET genes 
were enriched in were: IL23-mediated signaling events; PI3K-Akt signaling pathway; histidine, 
lysine, phenylalanine, tyrosine, proline, and tryptophan catabolism; hypoxia and p53 in the 
cardiovascular system; and the mTOR signaling pathway.  
 Many of the treatments shared pathway enrichments (ST8, Appendix). There were zero 
common pathways for the four MET-induced treatments, and when PC3+miR-429 was 
excluded, there were 94 common pathways between HEY+miR-429, HEY+miR-205, and 
PC3+miR-203a. When PC3+miR-205 was included with they MET-inducing HEY samples and 
PC3+miR-203a, there were 85 common pathway enrichments. Excluding any miR-429 
treatments, when comparing PC3+miR-203a and HEY+miR-205 pathway enrichments, they 
shared 131 pathways. When comparing the miR-429 treatments, between the 161 pathway 
enrichments of HEY+miR-429 and 13 pathway enrichments of PC3+miR-429, there were no 
common enrichments. When comparing the miR-203a treatments, there was one pathway, 
extracellular matrix organization, that was shared between the six pathway enrichments of 
HEY+miR-203a and 260 enrichments of HEY+miR-203a. For the miR-205 treatments, there were 
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124 shared pathway enrichments between the 255 enrichments of HEY+miR-205 and 218 
enrichments of PC3+miR-205.  
 
DISCUSSION 
 In this study we demonstrate that the same microRNA (miR-429) can exhibit 
mesenchymal-to-epithelial transition in different cell lines that share phenotypic characteristics 
(HEY and PC3). By contrast, the two other microRNAs of interest in this study, miR-203a and 
miR-205, only induced MET in PC3 and HEY, respectively, but not both. We also demonstrate 
that for miR-203a and miR-205, the number of differentially expressed genes in each cell line is 
related to if MET was induced. The samples that did not induce MET (miR-203a+HEY and miR-
205+PC3) have less DE genes than their counterparts that did induce it, which is expected since 
a morphological change is not observed. We expect that those treatments that induce MET 
would have more differentially expressed genes than those that do not, since a biological 
process is being induced within the cell. However, this trend does not hold true for the miR-429 
overexpressed treatments. PC3 cells transfected with miR-429 showed 1,447 DE genes, while 
HEY transfected with the same microRNA showed 7,179 genes. It is unclear why PC3 cells have 
much fewer DE genes than HEY when both are transfected with miR-429. To elucidate why this 
may be the case, we compared the number of putative direct microRNA targets to our DE gene 
results, which revealed that 27% of PC3+miR-429’s DE genes are direct putative targets of miR-
429 (Figure 4). Comparing this to HEY+miR-429’s DE genes, which had only 19% as putative 
direct targets of miR-429, this suggests that miR-429 induces MET in PC3 cells in a more direct 
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manner than it does in HEY. It may be that miR-429’s induction of MET in HEY is driven more by 
the indirect effects of the microRNA, and in PC3 cells MET is induced primarily through the 
direct targets of miR-429.  Further studies focused on the intersection of the differentially 
expressed genes in these two cell lines transfected with miR-429 may reveal genes common to 
both that induce a full MET process in PC3 and at least a partial induction of MET in HEY cells. 
Regarding the putative direct targets’ relationship with the DE genes of other treatments that 
did or did not induce MET, there is not a clear relationship that demonstrates that the 
treatments that showed MET had a higher percentage of putative direct microRNA targets, and 
vice versa for those that did not demonstrate MET.  
 Another goal of this study was to identify a gene target for siRNA knockdown which may 
help elucidate a mechanism by which miR-429, miR-203a, and miR-205 induce MET in the cell 
lines. Based on aggregating the most common DE genes of all four samples that induced MET 
(HEY + miR-429, PC3 + miR-429, HEY + miR-205, and PC3 + miR-203a), which gave a list of 312 
genes (figure 5), and then comparing these genes to Qiagen’s list of EMT genes, four genes 
were identified as preliminary gene targets of interest: GNG11, TCF4, WNT5A, and ZEB1. Of 
these four, ZEB1 was identified as the primary siRNA knockdown candidate because it was a 
target of all three microRNAs of interest in this study, as well as due to its extensive 
involvement in EMT and many pathways involved in EMT [26]. 
The four genes are all implicated in EMT processes. GNG11, as classified by Qiagen’s 
EMT list, is involved in G-protein coupled receptors in signaling pathways and normally 
upregulated during EMT. TCF4 is a transcription factor that binds with β-catenin to the 
promoter region of ZEB1 to induce its expression, and is normally upregulated during EMT [24]. 
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WNT5A is involved in differentiation and development and upregulated during EMT, per 
Qiagen’s list. It is also reported that WNT5A is involved in the regulation of cancer cell invasion, 
metastasis, metabolism, and inflammation [25]. Finally, ZEB1, per Qiagen’s list, is involved in 
cell growth and proliferation, and is a transcription factor involved in EMT. It well-covered in 
the literature that ZEB1 is regulated by multiple signaling pathways, including WNT, NF-kB, TGF-
β, and with the miR-200 family and miR-205 [26]. ZEB1’s role of binding to the promoter of 
CDH1, the gene encoding E-cadherin, and repressing the expression of E-cadherin, thereby 
inducing EMT, is also well-reported [26]. ZEB1 acts in a double negative feedback loop with the 
miR-200 family to induce EMT when the miR-200 family is repressed [28]. It has also been 
shown to inhibit the expression of stemness-repressing microRNAs, including miR-203 and the 
miR-200 family, thereby increasing the tumorigenicity of pancreatic cancer cells [27].  ZEB1’s 
role in EMT/MET is well-reported, and as such, it serves as a promising siRNA knockdown 
candidate to recapitulate MET. However, due to the inter-relatedness of genes involved in 
metastasis and EMT/MET, it is possible that ZEB1 knockdown may fail to recapitulate MET to 
the degree with which it was observed with the microRNAs. In this case, it is likely that the 
induction of MET with microRNAs is driven more so by the indirect effects of the microRNAs 
rather than its direct targets. This would be confirmed by siRNA knockdown of ZEB1 and 
resulting microarray analysis.  
 In order to understand how the microRNAs induced changes in gene expression, 
pathway enrichment of each treatment sample was done.  For the miR-429 treatments, there 
were no common pathways enriched for HEY and PC3 cells. PC3+miR-429 pathway enrichments 
revealed enrichment for pathways such as cell junction organization, adherens junctions 
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interactions, and extracellular matrix organization, which are involved in cell adhesion changes 
affected by MET (ST4, Appendix). By contrast, the top enrichments for HEY+miR-429 are mostly 
involved in mitochondrial translation, gene expression, and cell cycle control. Because miR-429 
induces MET in both HEY and PC3, these different enrichments suggest that miR-429 induces 
MET by different pathways in each cell line. The two other treatments that induced MET, 
PC3+miR-203a and HEY+miR-205, shared 131 pathways. This suggests there is some similarity in 
how MET is induced by these two microRNAs in HEY and PC3 cells, and these 131 pathways are 
each about 50% of the pathways enriched in these two treatments. Of note, inhibition of the 
mTOR signaling pathway, which is enriched in HEY+miR-205, PC3+ miR-203a, and the 312 MET 
gene list has been shown to cancel TGF-beta1 induced EMT in cervical cancer cells [23]. For the 
miR-205 treatments, there were 124 shared pathways, and although miR-205 did not induce 
MET in both cell lines, this suggests that miR-205 works through the many of the same 
pathways in both cell lines, but there are more indirect effects at play to induce MET in HEY 
cells. For the miR-203a treatments, there was only one shared pathway, extracellular matrix 
organization. This single shared pathway in two treatments that do not both show MET when 
using the same microRNA suggests that miR-203a induced MET in PC3 cells through a 
completely separate pathway than through which it may have acted on HEY cells.  
 All treatments showed enrichment in at least one of the pathways known to be involved 
in EMT/MET (highlighted in red on ST8), such as cell cycle, mitotic G2-G2/M phases, 
extracellular matrix organization, and mCalpain and friends in cell motility, among many others. 
The cellular stress response pathway was also enriched, which is due to the stress of 
transfection with Lipofectamine 2000. The six treatments that showed MET after 
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overexpression of one of the microRNAs were not all enriched in the same pathway at once, 
but there were different combinations of common enrichment (ST8, Appendix). Examples of 
such combinations include cell cycle and hedgehog ‘on’ state pathway enrichment which were 
enriched in HEY+429, HEY+205, PC3+203a, and PC3+205 (ST8, Appendix). Cell cycle arrest is 
common in EMT induction, many times arresting the cell at the G2 checkpoint [21]. Activation 
of the hedgehog pathway has been reported to indirectly induce EMT through FGF, Notch, TGF-
beta signaling cascades, and microRNA regulatory networks [22]. These pathways have been 
shown to be induced in EMT, but PC3+miR-205 was not one of the MET-inducing treatments, 
which suggests that there are other pathways significant to prevent MET from occurring in PC3 
cells when miR-205 is overexpressed. Not all pathways enriched are necessarily implicated in 
EMT/MET, as many of the enrichment results are quite general, such as ‘gene expression.’ Our 
study shows a more global understanding of the relationships between how microRNAs behave 
in similar cell lines. 
 
CONCLUSION 
In this study we provide many observations on how different microRNAs that have been 
shown to be involved in epithelial-to-mesenchymal transition successfully or unsuccessfully 
induce MET in two mesenchymal-like cell lines representative of ovarian and prostate cancer. 
Future work can further elucidate specific mechanisms of MET/EMT in different cell lines, 
beginning with the knockdown of ZEB1 as this study reveals it as a promising candidate to 
recapitulate MET. However, it is possible that the single-gene nature of using siRNA knockdown 
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of ZEB1 will be insufficient to recapitulate the complex process of MET. In this case, different 
combinations of gene targets may be used to attempt to recapitulate MET. However, if ZEB1 
successfully recapitulates MET further studies may determine delivery methods of ZEB1 that 
can make it a useful therapeutic. Further work may also include studying these microRNAs in 
additional ovarian and prostate cancer cell lines to continue to pinpoint mechanisms that are 
similar in the induction of MET.  
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Supplementary Tables (ST) 
ST 1. HEY + miR-429 pathway enrichment results – top 50 pathway enrichments of 160 
(ToppGene, FDR: p < 0.05) 
Name Source p-value 
Gene Expression BioSystems: REACTOME 9.42E-18 
Organelle biogenesis and maintenance BioSystems: REACTOME 4.56E-12 
Mitochondrial translation initiation BioSystems: REACTOME 1.27E-10 
Mitochondrial translation elongation BioSystems: REACTOME 2.37E-10 
Mitochondrial translation BioSystems: REACTOME 5.78E-10 
Mitochondrial translation termination BioSystems: REACTOME 1.91E-09 
Cell Cycle BioSystems: REACTOME 2.78E-09 
Generic Transcription Pathway BioSystems: REACTOME 5.20E-09 
Metabolism of proteins BioSystems: REACTOME 5.69E-09 
Cell Cycle, Mitotic BioSystems: REACTOME 3.91E-08 
Respiratory electron transport, ATP synthesis by 
chemiosmotic coupling, and heat production by 
uncoupling proteins. BioSystems: REACTOME 5.55E-08 
Respiratory electron transport BioSystems: REACTOME 1.07E-07 
Mitotic G2-G2/M phases BioSystems: REACTOME 1.87E-07 
G2/M Transition BioSystems: REACTOME 2.27E-07 
The citric acid (TCA) cycle and respiratory 
electron transport BioSystems: REACTOME 2.38E-07 
Post-translational protein modification BioSystems: REACTOME 6.18E-07 
Validated targets of C-MYC transcriptional 
activation 
BioSystems: Pathway 
Interaction Database 8.31E-07 
Cellular responses to stress BioSystems: REACTOME 9.61E-07 
S Phase BioSystems: REACTOME 1.29E-06 
Lysine degradation BioSystems: KEGG 1.76E-06 
Oxidative phosphorylation BioSystems: KEGG 1.80E-06 
The role of GTSE1 in G2/M progression after G2 
checkpoint BioSystems: REACTOME 4.27E-06 
Non-alcoholic fatty liver disease (NAFLD) BioSystems: KEGG 4.45E-06 
Regulation of ornithine decarboxylase (ODC) BioSystems: REACTOME 5.03E-06 
Synthesis of DNA BioSystems: REACTOME 5.78E-06 
APC/C:Cdh1 mediated degradation of Cdc20 and 
other APC/C:Cdh1 targeted proteins in late 
mitosis/early G1 BioSystems: REACTOME 1.27E-05 
Cyclin A:Cdk2-associated events at S phase entry BioSystems: REACTOME 1.55E-05 
TP53 Regulates Metabolic Genes BioSystems: REACTOME 1.93E-05 
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oxidative phosphorylation Pathway Ontology 2.07E-05 
Cyclin E associated events during G1/S transition BioSystems: REACTOME 2.34E-05 
Golgi Associated Vesicle Biogenesis BioSystems: REACTOME 2.37E-05 
Chromosome Maintenance BioSystems: REACTOME 2.60E-05 
Asparagine N-linked glycosylation BioSystems: REACTOME 2.90E-05 
Cilium Assembly BioSystems: REACTOME 3.22E-05 
Antigen processing-Cross presentation BioSystems: REACTOME 3.40E-05 
APC/C:Cdc20 mediated degradation of Securin BioSystems: REACTOME 3.46E-05 
DNA Replication BioSystems: REACTOME 3.57E-05 
PCP/CE pathway BioSystems: REACTOME 3.62E-05 
SCF(Skp2)-mediated degradation of p27/p21 BioSystems: REACTOME 4.06E-05 
Degradation of DVL BioSystems: REACTOME 4.92E-05 
Autodegradation of Cdh1 by Cdh1:APC/C BioSystems: REACTOME 5.12E-05 
Membrane Trafficking BioSystems: REACTOME 5.46E-05 
Ubiquitin-dependent degradation of Cyclin D BioSystems: REACTOME 5.54E-05 
Ubiquitin-dependent degradation of Cyclin D1 BioSystems: REACTOME 5.54E-05 
Extension of Telomeres BioSystems: REACTOME 5.58E-05 
AUF1 (hnRNP D0) binds and destabilizes mRNA BioSystems: REACTOME 5.97E-05 
G1/S DNA Damage Checkpoints BioSystems: REACTOME 6.32E-05 
MAPK6/MAPK4 signaling BioSystems: REACTOME 6.53E-05 
Proteasome BioSystems: KEGG 7.06E-05 
p53-Dependent G1/S DNA damage checkpoint BioSystems: REACTOME 7.70E-05 
 
ST2. HEY + miR-203a pathway enrichment results - all pathway enrichments (ToppGene, FDR: p 
< 0.05) 
Name Source p-value 
Cytokine-cytokine receptor interaction BioSystems: KEGG 1.30E-05 
Starch and Sucrose Metabolism SMPDB 2.23E-05 
Digestion of dietary carbohydrate BioSystems: REACTOME 3.26E-05 
Extracellular matrix organization BioSystems: REACTOME 3.66E-05 
Starch and sucrose metabolism BioSystems: KEGG 5.11E-05 
Rheumatoid arthritis BioSystems: KEGG 1.40E-04 
 
ST3. HEY + miR-205 pathway enrichment results – top 50 of 255 pathway enrichments 
(ToppGene, FDR: p < 0.05) 
Name Source p-value 
Gene Expression BioSystems: REACTOME 1.23E-17 
Metabolism BioSystems: REACTOME 1.95E-15 
Metabolic pathways BioSystems: KEGG 8.36E-15 
Cell Cycle, Mitotic BioSystems: REACTOME 1.16E-11 
Cell Cycle BioSystems: REACTOME 1.06E-10 
Asparagine N-linked glycosylation BioSystems: REACTOME 6.79E-10 
Cellular responses to stress BioSystems: REACTOME 7.83E-10 
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Organelle biogenesis and maintenance BioSystems: REACTOME 2.04E-09 
Metabolism of proteins BioSystems: REACTOME 3.33E-09 
Membrane Trafficking BioSystems: REACTOME 8.15E-09 
Class I MHC mediated antigen processing & presentation BioSystems: REACTOME 8.84E-09 
Post-translational protein modification BioSystems: REACTOME 1.45E-07 
Vesicle-mediated transport BioSystems: REACTOME 1.47E-07 
G2/M Transition BioSystems: REACTOME 1.82E-07 
Mitotic Metaphase and Anaphase BioSystems: REACTOME 1.87E-07 
Antigen processing: Ubiquitination & Proteasome degradation BioSystems: REACTOME 2.26E-07 
Mitotic Anaphase BioSystems: REACTOME 2.80E-07 
The citric acid (TCA) cycle and respiratory electron transport BioSystems: REACTOME 3.14E-07 
Mitotic G2-G2/M phases BioSystems: REACTOME 3.85E-07 
Mitochondrial translation initiation BioSystems: REACTOME 4.26E-07 
M Phase BioSystems: REACTOME 1.04E-06 
Separation of Sister Chromatids BioSystems: REACTOME 2.19E-06 
Mitochondrial translation BioSystems: REACTOME 2.33E-06 
Transcriptional Regulation by TP53 BioSystems: REACTOME 2.42E-06 
PKB-mediated events BioSystems: REACTOME 2.65E-06 
TP53 Regulates Metabolic Genes BioSystems: REACTOME 3.48E-06 
S Phase BioSystems: REACTOME 3.51E-06 
Mitochondrial translation termination BioSystems: REACTOME 3.57E-06 
Metabolism of lipids and lipoproteins BioSystems: REACTOME 3.97E-06 
Biosynthesis of amino acids BioSystems: KEGG 4.84E-06 
mTOR signalling BioSystems: REACTOME 5.13E-06 
Mitochondrial translation elongation BioSystems: REACTOME 5.95E-06 
Regulation of mRNA stability by proteins that bind AU-rich 
elements BioSystems: REACTOME 6.11E-06 
Processing of Capped Intron-Containing Pre-mRNA BioSystems: REACTOME 6.19E-06 
Synthesis of DNA BioSystems: REACTOME 6.26E-06 
Parkinson's disease BioSystems: KEGG 6.98E-06 
COPII (Coat Protein 2) Mediated Vesicle Transport BioSystems: REACTOME 7.45E-06 
Beta-catenin independent WNT signaling BioSystems: REACTOME 8.93E-06 
Cyclin A:Cdk2-associated events at S phase entry BioSystems: REACTOME 1.36E-05 
Cdc20:Phospho-APC/C mediated degradation of Cyclin A BioSystems: REACTOME 1.40E-05 
Transport to the Golgi and subsequent modification BioSystems: REACTOME 1.43E-05 
Regulation of APC/C activators between G1/S and early anaphase BioSystems: REACTOME 1.52E-05 
Respiratory electron transport BioSystems: REACTOME 1.53E-05 
Signaling by Wnt BioSystems: REACTOME 1.54E-05 
ER to Golgi Anterograde Transport BioSystems: REACTOME 1.68E-05 
mRNA Splicing BioSystems: REACTOME 2.02E-05 
APC:Cdc20 mediated degradation of cell cycle proteins prior to 
satisfation of the cell cycle checkpoint BioSystems: REACTOME 2.35E-05 
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Biosynthesis of the N-glycan precursor (dolichol lipid-linked 
oligosaccharide, LLO) and transfer to a nascent protein BioSystems: REACTOME 2.39E-05 
RNA transport BioSystems: KEGG 2.50E-05 
Energy dependent regulation of mTOR by LKB1-AMPK BioSystems: REACTOME 2.80E-05 
 
ST4. PC3 + miR-429 pathway enrichment results - all pathway enrichments (ToppGene, FDR: p < 
0.05) 
Name Source p-value 
Cell junction organization BioSystems: REACTOME 6.58E-07 
Proteoglycans in cancer BioSystems: KEGG 6.84E-07 
Cell-cell junction organization BioSystems: REACTOME 1.22E-06 
Hippo signaling pathway BioSystems: KEGG 5.07E-06 
Pathways in cancer BioSystems: KEGG 6.50E-06 
Cell-Cell communication BioSystems: REACTOME 1.33E-05 
Adherens junctions interactions BioSystems: REACTOME 1.46E-05 
Fluid shear stress and atherosclerosis BioSystems: KEGG 3.49E-05 
Glycosaminoglycan metabolism BioSystems: REACTOME 4.35E-05 
Signaling by MST1 BioSystems: REACTOME 8.04E-05 
mucin core 1 and core 2 O-glycosylation BioSystems: BIOCYC 1.14E-04 
Amoebiasis BioSystems: KEGG 1.17E-04 
Extracellular matrix organization BioSystems: REACTOME 1.85E-04 
 
ST5. PC3 + miR-203a pathway enrichment results – top 50 of 261 pathway enrichments 
(ToppGene, FDR: p < 0.05) 
Name Source p-value 
Gene Expression BioSystems: REACTOME 1.42E-20 
Metabolism of proteins BioSystems: REACTOME 3.66E-15 
Metabolism BioSystems: REACTOME 2.54E-12 
rRNA processing in the nucleus and cytosol BioSystems: REACTOME 2.00E-11 
Organelle biogenesis and maintenance BioSystems: REACTOME 3.90E-11 
rRNA processing BioSystems: REACTOME 5.53E-11 
Infectious disease BioSystems: REACTOME 1.08E-10 
Cell Cycle, Mitotic BioSystems: REACTOME 2.18E-10 
Mitochondrial translation initiation BioSystems: REACTOME 2.47E-10 
Ribosome BioSystems: KEGG 4.17E-10 
Mitochondrial translation elongation BioSystems: REACTOME 4.59E-10 
Translation BioSystems: REACTOME 6.98E-10 
Major pathway of rRNA processing in the nucleolus and cytosol BioSystems: REACTOME 1.09E-09 
Mitochondrial translation BioSystems: REACTOME 1.13E-09 
Mitotic G2-G2/M phases BioSystems: REACTOME 2.70E-09 
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Mitochondrial translation termination BioSystems: REACTOME 3.56E-09 
Eukaryotic Translation Elongation BioSystems: REACTOME 5.74E-09 
Metabolism of amino acids and derivatives BioSystems: REACTOME 7.62E-09 
G2/M Transition BioSystems: REACTOME 7.90E-09 
Cell Cycle BioSystems: REACTOME 8.47E-09 
Formation of a pool of free 40S subunits BioSystems: REACTOME 1.55E-08 
GTP hydrolysis and joining of the 60S ribosomal subunit BioSystems: REACTOME 1.61E-08 
L13a-mediated translational silencing of Ceruloplasmin 
expression BioSystems: REACTOME 1.61E-08 
Eukaryotic Translation Initiation BioSystems: REACTOME 2.22E-08 
Cap-dependent Translation Initiation BioSystems: REACTOME 2.22E-08 
SRP-dependent cotranslational protein targeting to membrane BioSystems: REACTOME 3.56E-08 
Eukaryotic Translation Termination BioSystems: REACTOME 3.62E-08 
Cellular responses to stress BioSystems: REACTOME 5.06E-08 
Peptide chain elongation BioSystems: REACTOME 5.07E-08 
Viral mRNA Translation BioSystems: REACTOME 1.58E-07 
Selenocysteine synthesis BioSystems: REACTOME 2.10E-07 
Metabolic pathways BioSystems: KEGG 2.25E-07 
Disease BioSystems: REACTOME 2.46E-07 
UCH proteinases BioSystems: REACTOME 3.76E-07 
Nonsense Mediated Decay (NMD) independent of the Exon 
Junction Complex (EJC) BioSystems: REACTOME 4.25E-07 
Membrane Trafficking BioSystems: REACTOME 4.69E-07 
Regulation of mRNA stability by proteins that bind AU-rich 
elements BioSystems: REACTOME 4.70E-07 
Antigen processing-Cross presentation BioSystems: REACTOME 5.41E-07 
ER-Phagosome pathway BioSystems: REACTOME 7.99E-07 
Influenza Infection BioSystems: REACTOME 1.11E-06 
Asparagine N-linked glycosylation BioSystems: REACTOME 1.26E-06 
Unfolded Protein Response (UPR) BioSystems: REACTOME 1.34E-06 
Influenza Viral RNA Transcription and Replication BioSystems: REACTOME 1.35E-06 
Selenoamino acid metabolism BioSystems: REACTOME 1.48E-06 
Influenza Life Cycle BioSystems: REACTOME 2.04E-06 
Vesicle-mediated transport BioSystems: REACTOME 3.20E-06 
HIV Infection BioSystems: REACTOME 3.53E-06 
Post-translational protein modification BioSystems: REACTOME 4.85E-06 
Metabolism of carbohydrates BioSystems: REACTOME 4.86E-06 
FBXL7 down-regulates AURKA during mitotic entry and in early 
mitosis BioSystems: REACTOME 5.31E-06 
 
ST6. PC3 + miR-205 pathway enrichment results – top 50 of 218 pathways enriched – 
(ToppGene, FDR: p < 0.05) 
Name Source p-value 
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Interferon alpha/beta signaling BioSystems: REACTOME 6.87E-13 
Gene Expression BioSystems: REACTOME 5.58E-11 
Cell Cycle, Mitotic BioSystems: REACTOME 7.31E-11 
Metabolism BioSystems: REACTOME 3.25E-10 
Metabolism of proteins BioSystems: REACTOME 1.72E-09 
ER-Phagosome pathway BioSystems: REACTOME 3.27E-09 
Interferon Signaling BioSystems: REACTOME 5.90E-09 
Cell Cycle BioSystems: REACTOME 6.13E-09 
Protein processing in endoplasmic reticulum BioSystems: KEGG 9.98E-09 
Cytokine Signaling in Immune system BioSystems: REACTOME 2.97E-08 
Immune System BioSystems: REACTOME 3.33E-08 
Cellular responses to stress BioSystems: REACTOME 3.90E-08 
G2/M Transition BioSystems: REACTOME 6.93E-08 
M Phase BioSystems: REACTOME 9.55E-08 
Mitochondrial translation elongation BioSystems: REACTOME 1.00E-07 
Mitotic G2-G2/M phases BioSystems: REACTOME 1.22E-07 
Metabolism of amino acids and derivatives BioSystems: REACTOME 1.36E-07 
rRNA processing in the nucleus and cytosol BioSystems: REACTOME 1.61E-07 
Mitochondrial translation initiation BioSystems: REACTOME 2.07E-07 
rRNA processing BioSystems: REACTOME 2.08E-07 
Mitochondrial translation BioSystems: REACTOME 3.99E-07 
Unfolded Protein Response (UPR) BioSystems: REACTOME 5.33E-07 
Translation BioSystems: REACTOME 6.01E-07 
Mitochondrial translation termination BioSystems: REACTOME 6.38E-07 
Antigen processing-Cross presentation BioSystems: REACTOME 1.01E-06 
SCF(Skp2)-mediated degradation of p27/p21 BioSystems: REACTOME 1.26E-06 
The role of GTSE1 in G2/M progression after G2 checkpoint BioSystems: REACTOME 1.26E-06 
Infectious disease BioSystems: REACTOME 1.32E-06 
Major pathway of rRNA processing in the nucleolus and cytosol BioSystems: REACTOME 1.71E-06 
Ribosome BioSystems: KEGG 1.75E-06 
Regulation of mRNA stability by proteins that bind AU-rich 
elements BioSystems: REACTOME 4.27E-06 
Organelle biogenesis and maintenance BioSystems: REACTOME 4.27E-06 
Cyclin E associated events during G1/S transition BioSystems: REACTOME 4.89E-06 
Biosynthesis of amino acids BioSystems: KEGG 7.29E-06 
IRE1alpha activates chaperones BioSystems: REACTOME 7.72E-06 
p53-Dependent G1/S DNA damage checkpoint BioSystems: REACTOME 7.75E-06 
p53-Dependent G1 DNA Damage Response BioSystems: REACTOME 7.75E-06 
Mitotic Metaphase and Anaphase BioSystems: REACTOME 9.41E-06 
Cyclin A:Cdk2-associated events at S phase entry BioSystems: REACTOME 9.76E-06 
XBP1(S) activates chaperone genes BioSystems: REACTOME 1.03E-05 
Hh mutants that don't undergo autocatalytic processing are 
degraded by ERAD BioSystems: REACTOME 1.21E-05 
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Mitotic Anaphase BioSystems: REACTOME 1.51E-05 
Class I MHC mediated antigen processing & presentation BioSystems: REACTOME 1.63E-05 
G1/S DNA Damage Checkpoints BioSystems: REACTOME 1.75E-05 
Hedgehog ligand biogenesis BioSystems: REACTOME 1.75E-05 
Respiratory electron transport BioSystems: REACTOME 1.76E-05 
Eukaryotic Translation Initiation BioSystems: REACTOME 1.95E-05 
Cap-dependent Translation Initiation BioSystems: REACTOME 1.95E-05 
Membrane Trafficking BioSystems: REACTOME 2.24E-05 
Eukaryotic Translation Elongation BioSystems: REACTOME 2.26E-05 
 
ST7. 312 MET genes pathway enrichment results 
Name Source p-value 
IL23-mediated signaling events 
BioSystems: Pathway 
Interaction Database 1.37E-03 
PI3K-Akt signaling pathway BioSystems: KEGG 1.90E-03 
Histidine, lysine, phenylalanine, tyrosine, proline and 
tryptophan catabolism BioSystems: REACTOME 2.84E-03 
Hypoxia and p53 in the Cardiovascular system MSigDB C2 BIOCARTA (v6.0) 3.28E-03 
mTOR signaling pathway BioSystems: KEGG 3.83E-03 
mCalpain and friends in Cell motility MSigDB C2 BIOCARTA (v6.0) 4.17E-03 
Toll receptor signaling pathway PantherDB 4.17E-03 
ECM-receptor interaction BioSystems: KEGG 4.50E-03 
Synthesis of diphthamide-EEF2 BioSystems: REACTOME 4.58E-03 
CHL1 interactions BioSystems: REACTOME 5.84E-03 
Longevity regulating pathway BioSystems: KEGG 6.37E-03 
Ca-dependent events BioSystems: REACTOME 7.02E-03 
Collagen formation BioSystems: REACTOME 7.65E-03 
Amoebiasis BioSystems: KEGG 8.71E-03 
IRAK4 deficiency (TLR2/4) BioSystems: REACTOME 8.77E-03 
MyD88 deficiency (TLR2/4) BioSystems: REACTOME 8.77E-03 
Inflammatory mediator regulation of TRP channels BioSystems: KEGG 9.09E-03 
Glucagon signaling in metabolic regulation BioSystems: REACTOME 9.17E-03 
AKAP95 role in mitosis and chromosome dynamics MSigDB C2 BIOCARTA (v6.0) 1.04E-02 
Cystic Fibrosis Transmembrane Conductance Regulator And 
Beta 2 Adrenergic Receptor Pathway MSigDB C2 BIOCARTA (v6.0) 1.04E-02 
IL1-mediated signaling events 
BioSystems: Pathway 
Interaction Database 1.08E-02 
Prion diseases BioSystems: KEGG 1.08E-02 
Signaling events mediated by TCPTP 
BioSystems: Pathway 
Interaction Database 1.17E-02 
GABA-B receptor II signaling PantherDB 1.17E-02 
Toll-like receptor signaling pathway BioSystems: KEGG 1.21E-02 
Aspartate Metabolism SMPDB 1.22E-02 
Notch-HLH transcription pathway BioSystems: REACTOME 1.22E-02 
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Platelet Adhesion to exposed collagen BioSystems: REACTOME 1.22E-02 
Argininosuccinic Aciduria SMPDB 1.34E-02 
oxidative stress responses Pathway Ontology 1.34E-02 
Methylmalonate Semialdehyde Dehydrogenase Deficiency SMPDB 1.34E-02 
Interleukin-6 signaling Pathway Ontology 1.34E-02 
Signaling events mediated by HDAC Class III 
BioSystems: Pathway 
Interaction Database 1.45E-02 
Endothelin signaling pathway PantherDB 1.56E-02 
Inositol Metabolism SMPDB 1.62E-02 
Protein Kinase A at the Centrosome MSigDB C2 BIOCARTA (v6.0) 1.62E-02 
Glycosphingolipid biosynthesis - globo and isoglobo series BioSystems: KEGG 1.62E-02 
The IGF-1 Receptor and Longevity MSigDB C2 BIOCARTA (v6.0) 1.62E-02 
Cholinergic synapse BioSystems: KEGG 1.62E-02 
Focal adhesion BioSystems: KEGG 1.63E-02 
Gastric acid secretion BioSystems: KEGG 1.71E-02 
Extracellular matrix organization BioSystems: REACTOME 1.72E-02 
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion BioSystems: REACTOME 1.77E-02 
Pertussis BioSystems: KEGG 1.79E-02 
Proteoglycans in cancer BioSystems: KEGG 1.80E-02 
Role of PI3K subunit p85 in regulation of Actin Organization 
and Cell Migration MSigDB C2 BIOCARTA (v6.0) 1.83E-02 
Regulation of TLR by endogenous ligand BioSystems: REACTOME 1.83E-02 
PKA activation BioSystems: REACTOME 1.83E-02 
B Cell Survival Pathway MSigDB C2 BIOCARTA (v6.0) 1.83E-02 
Vasopressin regulates renal water homeostasis via 
Aquaporins BioSystems: REACTOME 1.88E-02 
 
ST8. Summary of common pathway enrichment among miRNA treatments of HEY and PC3 cells 
(1 = pathway enriched, red text = pathways shown to be involved in EMT) 
ID Name H_429 H_203a H_205 P_429 P_203a P_205 312_MET 
1269649 Gene Expression 1  1  1 1  
1268838 
Organelle biogenesis 
and maintenance 1  1  1 1  
1268843 
Mitochondrial 




elongation 1  1  1 1  
1268842 
Mitochondrial 




termination 1  1  1 1  






Pathway 1  1  1   
1268677 
Metabolism of 
proteins 1  1  1 1  






coupling, and heat 
production by 
uncoupling proteins. 1  1  1 1  
1270128 
Respiratory electron 
transport 1  1  1 1  
1269797 
Mitotic G2-G2/M 
phases 1  1  1 1  
1269799 G2/M Transition 1  1  1 1  
1270121 
The citric acid (TCA) 
cycle and respiratory 
electron transport 1  1  1 1  
1268701 
Post-translational 
protein modification 1  1  1 1  
169351 
Validated targets of 
C-MYC 
transcriptional 
activation 1  1  1   
1270414 
Cellular responses to 
stress 1  1  1 1  
1269777 S Phase 1  1  1 1  
82942 
Oxidative 
phosphorylation 1  1  1   
1383017 
The role of GTSE1 in 
G2/M progression 
after G2 checkpoint 1  1  1 1  
862188 
Non-alcoholic fatty 




decarboxylase (ODC) 1  1  1 1  





Cdc20 and other 
APC/C:Cdh1 1  1  1 1  
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targeted proteins in 
late mitosis/early G1 
1269778 
Cyclin A:Cdk2-
associated events at 
S phase entry 1  1  1 1  
1269655 
TP53 Regulates 
Metabolic Genes 1  1   1  
PW:0000034 
oxidative 
phosphorylation 1  1  1   
1269769 
Cyclin E associated 
events during G1/S 
transition 1  1  1 1  
1269882 
Golgi Associated 
Vesicle Biogenesis 1  1     
1269853 
Chromosome 
Maintenance 1  1  1   
1268714 
Asparagine N-linked 
glycosylation 1  1  1 1  
1268846 Cilium Assembly 1  1  1   
1269195 
Antigen processing-





Securin 1  1  1 1  
1269875 DNA Replication 1  1  1 1  




p27/p21 1  1  1 1  
1269605 Degradation of DVL 1    1 1  
1269852 
Autodegradation of 
Cdh1 by Cdh1:APC/C 1  1  1 1  
1269877 
Membrane 








Cyclin D1 1  1  1 1  
1269857 
Extension of 




AUF1 (hnRNP D0) 
binds and 
destabilizes mRNA 1  1  1 1  
1269743 
G1/S DNA Damage 
Checkpoints 1  1  1 1  
1269506 
MAPK6/MAPK4 
signaling 1  1  1 1  








Response 1  1  1 1  
1427860 Deubiquitination 1  1  1 1  
1269725 
Regulation of mRNA 
stability by proteins 
that bind AU-rich 
elements 1  1  1 1  
1383018 
AURKA Activation by 






degradation 1  1  1 1  
1269881 
Clathrin derived 
vesicle budding 1  1     
1269880 
trans-Golgi Network 




during mitotic entry 
and in early mitosis 1    1 1  
1427861 UCH proteinases 1  1  1 1  
1269845 
APC:Cdc20 mediated 
degradation of cell 
cycle proteins prior 
to satisfation of the 
cell cycle checkpoint 1  1  1 1  
1270170 
Metabolism of 
polyamines 1  1  1 1  
1269640 Hedgehog 'on' state 1  1  1 1  
1270295 
Regulation of 
Apoptosis 1  1  1 1  
132956 Metabolic pathways 1  1  1 1  
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177876 RNA transport 1  1     
1269842 




mitotic proteins 1  1  1 1  
1268847 
Anchoring of the 
basal body to the 
plasma membrane 1  1  1 1  
1269197 
ER-Phagosome 
pathway 1    1 1  
1269612 
Asymmetric 
localization of PCP 
proteins 1  1  1 1  
1268934 
Defective CFTR 
causes cystic fibrosis 1    1 1  
1269808 





the centrosome 1  1  1 1  
1269809 
Loss of Nlp from 




APOBEC3G 1    1 1  
1269876 
Vesicle-mediated 
transport 1  1  1 1  
1269654 
Transcriptional 
Regulation by TP53 1  1  1 1  
1269742 
Cell Cycle 





Cyclin A 1  1  1 1  
125136 Spliceosome 1  1  1 1  
1269747 
Autodegradation of 
the E3 ubiquitin 
ligase COP1 1    1 1  
1268928 
















(endosomes) 1    1 1  




Response 1    1 1  
1269750 
p53-Independent 
G1/S DNA damage 










complexes 1  1  1 1  
1269805 
Centrosome 
maturation 1  1  1 1  
1269784 
DNA strand 






Factor Alpha 1    1   
83098 Parkinson's disease 1  1  1 1  
1427862 
Ub-specific 








signaling 1  1  1 1  
1269810 M Phase 1  1  1 1  
1270262 Apoptosis 1  1   1  
1270125 
Citric acid cycle (TCA 
cycle) 1  1     
1270261 
Programmed Cell 






secretion 1    1 1  
1339146 Complex I biogenesis 1  1  1 1  
1269768 G1/S Transition 1  1  1 1  
373901 HTLV-I infection 1      1 
1269825 Mitotic Anaphase 1  1  1 1  
1269599 
TCF dependent 
signaling in response 
to WNT 1  1  1 1  
1269290 
Regulation of RAS by 
GAPs 1  1  1 1  
1269838 
APC/C-mediated 
degradation of cell 
cycle proteins 1  1   1  
1269837 
Regulation of mitotic 
cell cycle 1  1   1  
1269107 
Vpu mediated 
degradation of CD4 1    1 1  
469200 Legionellosis 1     1 1 
1269304 
CLEC7A (Dectin-1) 
signaling 1  1  1 1  
1269637 
GLI3 is processed to 
GLI3R by the 
proteasome 1  1  1 1  
1269823 
Mitotic Metaphase 




degradation of Emi1 1  1  1 1  
1269764 
Mitotic G1-G1/S 
phases 1  1  1 1  
83097 Alzheimer's disease 1  1     
1269781 
Switching of origins 
to a post-replicative 
state 1  1  1 1  
1269782 
Orc1 removal from 
chromatin 1  1  1 1  
1269956 Metabolism 1  1  1 1  
1269594 Signaling by Wnt 1  1  1 1  
1270350 DNA Repair 1  1  1   
1269856 
Telomere 
Maintenance 1    1   
1269839 
Regulation of APC/C 
activators between 1  1   1  
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G1/S and early 
anaphase 
1269826 
Separation of Sister 
Chromatids 1  1  1 1  
1269331 
NIK-->noncanonical 
NF-kB signaling 1  1  1 1  
1268725 
Transport to the 
Golgi and 
subsequent 
modification 1  1  1   
1268726 
ER to Golgi 
Anterograde 
Transport 1  1     
1269796 
Removal of licensing 





mRNA 1  1  1 1  
1269794 
Regulation of DNA 




signaling 1  1  1 1  
1269638 
Degradation of GLI2 
by the proteasome 1    1 1  
1269833 
Assembly of the pre-
replicative complex 1    1 1  
1268933 
ABC transporter 
disorders 1    1 1  
1270367 DNA Damage Bypass 1     1  
1269803 
Regulation of PLK1 
Activity at G2/M 
Transition 1    1 1  
1269606 Degradation of AXIN 1  1  1 1  
1269689 mRNA Splicing 1  1  1 1  
1269831 M/G1 Transition 1    1 1  
1269832 
DNA Replication Pre-
Initiation 1    1 1  
1269634 
Hedgehog ligand 
biogenesis 1    1 1  
1270244 
Extracellular matrix 
organization  1  1 1  1 
200309 Rheumatoid arthritis  1     1 
1268760 
XBP1(S) activates 
chaperone genes   1  1 1  
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83100 Huntington's disease   1  1   
1269690 
mRNA Splicing - 
Major Pathway   1  1   
1269957 
Metabolism of 
carbohydrates   1  1   
1269596 
Degradation of beta-
catenin by the 
destruction complex   1  1 1  
1270158 
Metabolism of 
amino acids and 
derivatives   1  1 1  
1457780 
Neutrophil 
degranulation   1  1 1  
1269056 Infectious disease   1  1 1  
1269171 
Adaptive Immune 
System   1   1  
814926 Carbon metabolism   1  1 1  
1269057 HIV Infection   1  1 1  
1269639 
Degradation of GLI1 
by the proteasome   1  1 1  
M8719 
mCalpain and friends 





and peptide loading 
of class I MHC   1   1  
1269170 Immune System   1  1 1  
1270426 Cellular Senescence   1  1 1  
1269821 
Resolution of Sister 




ER traffic   1  1 1  
138001 
mTOR signaling 
pathway   1  1   
SMP00011 Inositol Metabolism   1    1 
658418 Viral carcinogenesis   1  1 1 1 
1383086 
Major pathway of 
rRNA processing in 
the nucleolus and 
cytosol   1  1 1  
1319989 
Longevity regulating 





kappaB in B cells   1  1 1  
1427846 
rRNA processing in 
the nucleus and 




retrograde traffic   1  1 1  
1269959 Glucose metabolism   1  1 1  
1269883 
Lysosome Vesicle 
Biogenesis   1  1   
1383085 rRNA processing   1  1 1  
1269734 
Epigenetic 
regulation of gene 
expression   1  1   
M8873 
Fas Signaling 
Pathway   1  1   
1269633 
Signaling by 
Hedgehog   1  1 1  
1383087 
rRNA modification in 
the nucleus and 
cytosol   1  1 1  
M16563 
mTOR Signaling 
Pathway   1  1  1 
782000 
Proteoglycans in 
cancer    1   1 
83105 Pathways in cancer    1   1 
1474302 
Fluid shear stress 
and atherosclerosis    1 1 1  
167324 Amoebiasis    1   1 
83036 Ribosome     1 1  




Elongation     1 1  
1268681 
Formation of a pool 
of free 40S subunits     1 1  
1268686 
GTP hydrolysis and 
joining of the 60S 











Translation Initiation     1 1  
1268680 
Cap-dependent 




protein targeting to 




Termination     1 1  
1268691 
Peptide chain 
elongation     1 1  
1269120 
Viral mRNA 
Translation     1 1  
1339156 
Selenocysteine 
synthesis     1 1  




independent of the 
Exon Junction 
Complex (EJC)     1 1  
1269108 Influenza Infection     1 1  
1268756 
Unfolded Protein 
Response (UPR)     1 1  
1269115 
Influenza Viral RNA 
Transcription and 
Replication     1 1  
1339149 
Selenoamino acid 
metabolism     1 1  
1269109 Influenza Life Cycle     1 1  
1268759 
IRE1alpha activates 




enhanced by the 
Exon Junction 
Complex (EJC)     1 1  
1269716 
Nonsense-Mediated 
Decay (NMD)     1 1  
1268745 
Mitochondrial 
protein import     1 1  
1269091 
Host Interactions of 




Protein processing in 
endoplasmic 
reticulum     1 1  
1269329 
TNFR2 non-canonical 
NF-kB pathway     1 1  
1269753 G2/M Checkpoints     1 1  
1269192 
Class I MHC 
mediated antigen 
processing & 
presentation     1 1  
83059 
mTOR signaling 
pathway     1  1 
1269203 
Innate Immune 
System     1 1  
1269691 
mRNA Splicing - 





Senescence     1 1  
1383041 
Golgi-to-ER 




by TBK1/IKK epsilon     1  1 
PW:0000045 pentose phosphate     1 1  
790012 
Biosynthesis of 
amino acids     1 1  
1269509 
RHO GTPase 





1R signaling lead to 
BAD 





degradation     1 1  
83101 
Vibrio cholerae 
infection     1  1 
1268722 
N-glycan trimming in 
the ER and 
Calnexin/Calreticulin 
cycle     1 1  
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375172 Salmonella infection      1 1 
P00054 
Toll receptor 
signaling pathway      1 1 
1270245 Collagen formation      1 1 
1470924 
Interleukin-10 
signaling      1 1 
1269157 
Diseases associated 
with the TLR 
signaling cascade      1 1 
1269156 
Diseases of Immune 
System      1 1 
 
